Physician profile
Nathan Evan Osterman
NPI 1437531381
$3,038.00
in general payments reported to CMS, 2019-2025
15 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $429 · 2021: $485 · 2023: $322 · 2024: $991 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $718.07 | 2024-2025 | |
| Allergan, INC. | $649.85 | 2019-2021 | |
| Abbvie INC. | $528.45 | 2023-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $276.62 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $226.17 | 2020-2025 | Cequa |
| Alcon Vision LLC | $146.05 | 2021-2025 | Tryptyr, Eysuvis, Clareon |
| Glaukos Corporation | $111.42 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $102.88 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $73.79 | 2021-2023 | |
| Bausch & Lomb Americas INC. | $67.69 | 2023-2024 | Xiidra, Vyzulta, Miebo |
| Horizon Therapeutics Plc | $65.29 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $24.81 | 2020 | |
| Harrow Eye, LLC | $18.36 | 2025 | |
| Carl Zeiss Meditec, INC. | $17.03 | 2021 | |
| Kala Pharmaceuticals, INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Osterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.